(XHS) SPDR S&P Health Care - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A5737 • Health

XHS: Hospitals, Medical, Facilities, Laboratories, Insurance, Pharmaceuticals

The SPDR® S&P Health Care Services ETF (NYSE ARCA:XHS) is designed to provide exposure to the health care services sector by tracking the performance of the S&P Health Care Services Select Industry Index. The fund employs a sampling strategy, typically investing at least 80% of its total assets in securities that comprise the index. This approach allows for efficient tracking of the indexs performance while maintaining liquidity. The index itself is a subset of the S&P Total Market Index (S&P TMI), focusing specifically on companies within the health care services segment. This includes entities involved in health care equipment, services, and distributors. For more information, visit: http://www.spdrs.com.

As an ETF, XHS offers investors a targeted way to gain exposure to the health care services industry. Its investment strategy involves replicating the holdings and weightings of the S&P Health Care Services Select Industry Index, ensuring that the funds portfolio aligns closely with the indexs composition. The funds assets under management (AUM) total $82.56 million, indicating a moderate size that balances accessibility with diversification. This structure allows XHS to serve as a tool for investors seeking to capitalize on the growth and stability of the health care services sector within the broader market.

Based on the provided and , the 3-month outlook for XHS can be analyzed as follows: The funds short-term trend indicates strength, with the 20-day simple moving average (SMA) at 99.40, above the 50-day SMA of 97.19. This suggests positive momentum. However, the 200-day SMA at 95.03 indicates longer-term stability. The Average True Range (ATR) of 1.45 signals moderate volatility, while the average 20-day volume of 11,741 shares suggests lower liquidity compared to larger ETFs. Given these factors, XHS is expected to trade within a narrow range, with potential upside limited by the current price level of 97.86, which is near the 20-day SMA. Support is likely to hold around the 50-day SMA at 97.19. The fund may experience minor dips but is expected to remain stable overall, supported by its moderate AUM and the defensive nature of the health care services sector.

Additional Sources for XHS ETF

XHS ETF Overview

Market Cap in USD 84m
Category Health
TER 0.35%
IPO / Inception 2011-09-28

XHS ETF Ratings

Growth 5y 41.9%
Fundamental -
Dividend 43.7%
Rel. Strength Industry -5
Analysts -
Fair Price Momentum 86.77 USD
Fair Price DCF -

XHS Dividends

Dividend Yield 12m 0.36%
Yield on Cost 5y 0.67%
Annual Growth 5y 8.64%
Payout Consistency 73.2%

XHS Growth Ratios

Growth Correlation 3m 54%
Growth Correlation 12m 65.7%
Growth Correlation 5y 9.9%
CAGR 5y 13.21%
CAGR/Max DD 5y 0.41
Sharpe Ratio 12m 0.48
Alpha -4.00
Beta 0.65
Volatility 21.16%
Current Volume 2.2k
Average Volume 20d 6.2k
What is the price of XHS stocks?
As of March 14, 2025, the stock is trading at USD 93.56 with a total of 2,247 shares traded.
Over the past week, the price has changed by -3.16%, over one month by -7.68%, over three months by -0.68% and over the past year by +2.83%.
Is SPDR S&P Health Care a good stock to buy?
Partly, yes. Based on ValueRay Analyses, SPDR S&P Health Care (NYSE ARCA:XHS) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.85 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XHS as of March 2025 is 86.77. This means that XHS is currently overvalued and has a potential downside of -7.26%.
Is XHS a buy, sell or hold?
SPDR S&P Health Care has no consensus analysts rating.
What are the forecast for XHS stock price target?
According to ValueRays Forecast Model, XHS SPDR S&P Health Care will be worth about 96.2 in March 2026. The stock is currently trading at 93.56. This means that the stock has a potential upside of +2.82%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 96.2 2.8%